SynAct Pharma AB (8F8) Stock Statistics & Valuation Metrics

SynAct Pharma AB has a market cap or net worth of €84.62M. The enterprise value is €314.94M.

SynAct Pharma AB has 49,008,920 shares outstanding. The number of shares has decreased by -2.65% in one year.

SynAct Pharma AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of SynAct Pharma AB is -1.35. SynAct Pharma AB’s PEG ratio is -0.02.

In the last 12 months, SynAct Pharma AB had revenue of 0.00 and earned -215.81M in profits. Earnings per share was -6.64.

In the last 12 months, operating cash flow was -89.20M and capital expenditures 0.00, giving a free cash flow of -89.20M billion.

SynAct Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

SynAct Pharma AB upcoming earnings date is May 27, 2025, TBA Not Confirmed.

SynAct Pharma AB as a current ratio of 3.01, with Debt / Equity ratio of 0.88%

In the past 12 months, SynAct Pharma AB has paid -8.47M in taxes.

SynAct Pharma AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

SynAct Pharma AB has €61.21M in cash and marketable securities with kr1.88M in debt, giving a net cash position of -€59.33M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for SynAct Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―